An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2015
At a glance
- Drugs Polyphenon E (Primary) ; Green tea
- Indications Genital warts
- Focus Pharmacokinetics
- Sponsors MediGene AG
- 07 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Aug 2010 Planned end date changed from 1 Nov 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 10 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.